Crescita Therapeutics Inc
TSX:CTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Crescita Therapeutics Inc
Gross Profit
Crescita Therapeutics Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Crescita Therapeutics Inc
TSX:CTX
|
Gross Profit
CA$11.1m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Gross Profit
$7.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-1%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Gross Profit
CA$73.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Gross Profit
$62.8m
|
CAGR 3-Years
60%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Gross Profit
CA$207.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
21%
|
CAGR 10-Years
79%
|
|
Crescita Therapeutics Inc
Glance View
Crescita Therapeutics, Inc. engages in the provision of non-prescription skincare products. The company is headquartered in Mississauga, Ontario and currently employs 69 full-time employees. The company went IPO on 2016-03-07. The firm offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. The firm operates through three segments: Commercial Skincare, Licensing and Royalties and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products in both the Canadian and international markets. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis, MMPE and DuraPeel, on either an exclusive or non-exclusive basis. The Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization (CDMO) infrastructure, and sales of product development services.
See Also
What is Crescita Therapeutics Inc's Gross Profit?
Gross Profit
11.1m
CAD
Based on the financial report for Dec 31, 2025, Crescita Therapeutics Inc's Gross Profit amounts to 11.1m CAD.
What is Crescita Therapeutics Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
0%
Over the last year, the Gross Profit growth was 24%. The average annual Gross Profit growth rates for Crescita Therapeutics Inc have been -6% over the past three years .
